Near term planning for the globalisation of Penthrox
8 May 2015
ASX ANNOUNCEMENT
Near term planning for the globalisation of Penthrox
The approval of Penthrox for use in the United Kingdom, France, Belgium and Ireland validates our Regulatory Dossier and the clinical and safety data we have obtained for Penthrox. It proves Penthrox is a “world class” product which regulatory authorities around the world can approve for sale.
With the successful closure of the Decentralised Procedure (DP) and ultimate approval in Europe, MVP plans to aggressively expand the number of countries which can sell Penthrox:
For more information click on the link: ASX Announcement – Near term planning for the globalisation of Penthrox